NKGen Biotech (NKGN) announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator for its Phase 2a clinical ...

Australian antiviral drug development company Island Pharmaceuticals has completed subject dosing for the phase 2b ...

The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Acute and chronic treatment for hepatic encephalopathy acquired from Mallinckrodt Pharmaceuticals in September 2024Extended pre-clinical, clinical and IP package includes FDA and EMA orphan drug and ...

Study shows AP-325 offers lasting pain relief without central side effects Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

Detailed price information for Nervgen Pharma Corp (NGEN-X) from The Globe and Mail including charting and trades.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, and Vicore Pharma, a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 ...

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for ...

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once ...